Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Infections, Meningococcal Clinical Trial

Official title:

Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01165242
• Other study ID #: 114249
• Status: Completed
• Phase: Phase 2
• Start date: August 19, 2010
• Est. completion date: July 29, 2011

Study information

• Verified date: May 2018
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in subjects 10 through 25 years of age. In addition, this study will compare the immunogenicity of two lots of GSK 134612 vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1013
• Est. completion date: July 29, 2011
• Est. primary completion date: February 25, 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 10 Years to 25 Years

Eligibility

Inclusion Criteria:

All subjects must satisfy ALL of the following criteria at study entry:

• Subjects whom the investigator believes that they and/or their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.

• A male or female between, and including, 10 and 25 years of age at the time of the vaccination.

• Written informed consent obtained from the subject/from the parent or Legally Acceptable Representative(s) of the subject. Assent will be obtained from subjects who are still legally minors in line with local rules and regulations.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

• Previously completed routine childhood vaccinations to the best of subject's/Legally Acceptable Representative(s)'s knowledge.

• Female subjects of non-childbearing potential may be enrolled in the study.

• Female subjects of childbearing potential may be enrolled in the study, if the subject:

• has practiced adequate contraception for 30 days prior to vaccination, and

• has a negative pregnancy test on the day of vaccination, and

• has agreed to continue adequate contraception for 2 months after vaccination.

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:

• Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination. (For corticosteroids, this will mean prednisone <10 mg/day, or equivalent, is allowed. Inhaled and topical steroids are allowed.)

• Planned administration/administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine, with the exception of any licensed inactivated influenza vaccine.

• Previous vaccination with meningococcal polysaccharide or conjugate vaccine.

• Previous vaccination with vaccine components within the last month.

• History of meningococcal disease.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection, based on medical history and physical examination.

• A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.

• History of allergic reactions or disease likely to be exacerbated by any component of either vaccine, or by dry natural rubber latex.

• History of any neurologic disorders, including Guillain-Barré Syndrome.

• Major congenital defects or serious chronic illness.

• Acute disease at the time of enrollment.

• Administration of immunoglobulins and/or any blood products within the three months preceding the dose of study vaccine or planned administration during the study period.

• Pregnant or lactating female.

• History of chronic alcohol consumption and/or drug abuse.

• Female planning to become pregnant or planning to discontinue contraceptive precautions.

• Bleeding disorders, such as thrombocytopenia, or subjects on anti-coagulant therapy.

• Child in care.

• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.

Related Conditions & MeSH terms

• Infections, Meningococcal
• Meningococcal Infections

Intervention

Biological:
• Meningococcal vaccine GSK 134612
One intramuscular injection
• Menactra®
One intramuscular injection

Locations

Country	Name	City	State
Canada	GSK Investigational Site	Brampton	Ontario
Canada	GSK Investigational Site	Coquitlam	British Columbia
Canada	GSK Investigational Site	Halifax	Nova Scotia
Canada	GSK Investigational Site	Saint John's	Newfoundland and Labrador
Canada	GSK Investigational Site	Surrey	British Columbia
Canada	GSK Investigational Site	Toronto	Ontario
Canada	GSK Investigational Site	Winnipeg	Manitoba
Canada	GSK Investigational Site	Woodstock	Ontario
United States	GSK Investigational Site	Albany	Oregon
United States	GSK Investigational Site	Austin	Texas
United States	GSK Investigational Site	Carnegie	Pennsylvania
United States	GSK Investigational Site	Chandler	Arizona
United States	GSK Investigational Site	Columbia	Maryland
United States	GSK Investigational Site	Erie	Pennsylvania
United States	GSK Investigational Site	Erie	Pennsylvania
United States	GSK Investigational Site	Greer	South Carolina
United States	GSK Investigational Site	Hermitage	Pennsylvania
United States	GSK Investigational Site	Lexington	Kentucky
United States	GSK Investigational Site	Longmont	Colorado
United States	GSK Investigational Site	Marietta	Georgia
United States	GSK Investigational Site	Nicholasville	Kentucky
United States	GSK Investigational Site	Paramount	California
United States	GSK Investigational Site	Sacramento	California
United States	GSK Investigational Site	Sacramento	California
United States	GSK Investigational Site	Saint Louis	Missouri
United States	GSK Investigational Site	Santa Rosa	California
United States	GSK Investigational Site	Simpsonville	South Carolina
United States	GSK Investigational Site	Stevensville	Michigan
United States	GSK Investigational Site	Stockbridge	Georgia
United States	GSK Investigational Site	Syracuse	New York
United States	GSK Investigational Site	Wichita	Kansas
United States	GSK Investigational Site	Woodstock	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Vaccine Response to Serum Bactericidal Assay Using Human Complement Against Neisseria Meningitidis Serogroup A, C, W-135 and Y (hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY) Antibodies	Vaccine response was defined as: for initially seronegative subjects [with hSBA titer below (<) 1:4]: post-vaccination antibody titer greater than or equal to (=) 1:8 one month after vaccination; for initially seropositive subjects (with hSBA titer = 1:4): post-vaccination antibody titer = 4-fold the pre-vaccination antibody titer one month after vaccination.	One month after vaccination (Month 1)
Secondary	Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers = the Cut-off Value	The cut-off value for the hSBA-Men titers was greater than or equal to (=) 1:4.	Prior to (PRE) and one month after vaccination (Month 1)
Secondary	Number of Subjects With hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers = the Cut-off Value	The cut-off value for the hSBA-Men titers was greater than or equal to (=) 1:8.	Prior to (PRE) and one month after vaccination (Month 1)
Secondary	hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibody Titers	Antibody titers are presented as geometric mean titers (GMTs).	Prior to (PRE) and one month after vaccination (Month 1)
Secondary	Number of Subjects With Vaccine Response for hSBA-MenA, hSBA-MenC, hSBA-MenW-135 and hSBA-MenY Antibodies	Vaccine response was defined as: -for initially seronegative subjects [with hSBA titer below (<) 1:4]: post-vaccination antibody titer greater than or equal to (=) 1:8 one month after vaccination; -for initially seropositive subjects (with hSBA titer = 1:4): post-vaccination antibody titer = 4-fold the pre-vaccination antibody titer one month after vaccination.	One month after vaccination (Month 1)
Secondary	Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.	During the 4-day (Days 0-3) post-vaccination period
Secondary	Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms	Assessed solicited general symptoms were fatigue, gastrointestinal, headache and temperature [defined as oral temperature equal to or above (=) 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.	During the 4-day (Days 0-3) post-vaccination period
Secondary	Number of Subjects With Any Unsolicited Adverse Events (AEs)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	Within 31 days (Day 0-30) post-vaccination
Secondary	Number of Subjects With New Onset of Chronic Illness(es) (NOCI)	NOCI included hypersensitivity, insulin resistance, asthma and bronchial hyperreactivity.	From Month 0 through Month 6
Secondary	Number of Subjects With Any Serious Adverse Events (SAEs)	SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	From Month 0 through Month 6

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.